William Norman Birnie

OMNIlife science, Inc. manufactures orthopedic, prosthetic and other related products. The firm products are used in hip and knee replacement, joint pain and robotic surgery. The company was founded by Edward J. Cheal and George B. Cipolletti in 1999 and is headquartered in Raynham, MA.

Enztec Ltd. provides orthopedic medical devices. It specialises in creating orthopedic instrument solutions for implant companies and orthopedic surgeons worldwide. The firm offers bespoke design, manufacturing services and contract manufacturing. The company was founded by Paul Morrison and James Burn in 1992 and is headquartered in Christchurch, New Zealand.

Medical Innovations Ltd. develops and manufactures medical devices. It involves in the distribution of medical, dental, and hospital equipment and supplies. The company was founded on September 9, 2002 and is headquartered in Auckland, New Zealand.

Praxim SA manufactures and sells orthopedic surgical instruments. It specializes in minimal invasive products for knee arthroscopy. The company was founded by Stéphane Lavallée in 1995 and is headquartered in La Tronche, France.

Protemix Corporation is a biopharmaceutical company that discovers, develops and commercializes novel therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and their complications. Through cost-effective research in New Zealand, the company has assembled a pipeline of novel and innovative compounds, The most advanced compound is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix has assembled a pipeline of novel and innovative compounds, the most advanced of which is in Phase 2b FDA trials for the treatment of diabetic heart failure. Protemix’s discovery capabilities capitalize on the 30-year research expertise of the company’s founder, Professor Garth Cooper, a widely recognized expert in the field of peptide hormones, metabolic regulation and diabetes. The company’s discovery efforts are grounded in a detailed understanding of the potential mechanisms underlying diabetes and its complications, and have resulted in a pipeline of drug candidates that intervene at specific, well-defined disease targets to rebalance and renormalize key systems, thus enabling tissue repair and regeneration. Protemix’s lead compound, PX811019, is an orally active molecule that has shown the ability to reverse heart failure based on preclinical diabetic models and significantly reduced left ventricular hypertrophy in human clinic trials. Protemix studies suggest that PX811019 works by rebalancing abnormal copper accumulation in heart muscle, significantly improving cardiac structure and function without lowering blood glucose. The company has received Fast Track status for this compound from the U.S. Food and Drug Administration. The company has a second compound, PX811013, in late preclinical development for the treatment of both alcohol-mediated and non-alcoholic liver damage. The Protemix pipeline also includes six preclinical discovery programs addressing significant market opportunities. Protemix has its commercialization activities and late stage clinical trials driven from San Diego, California with administrative offices in Auckland, New Zealand and research laboratories at the University of Auckland. The company, founded in 1999, is privately held.

Enza Ltd. operated as a global marketing and distribution company specializing in pipfruit. The firm’s portfolio included apples, pears, kiwifruits, grapes, citrus fruits, stone fruits, mangoes, pineapples and greenhouse products. The company was incorporated on April 01, 2000 and was headquartered in Wellington, New Zealand.

New Zealand Film Commission provides funding and support services to New Zealand’s screen industry through creating and promoting films. The company is headquartered in Wellington, New Zealand.